20/20 BioLabs Reports Record OneTest Revenue, Eyes Broader Commercial Expansion — 20/20 Biolabs, Inc.

Event summary

20/20 BioLabs reported record OneTest revenue of $0.7M in Q2 2026, up 47.1% YoY.
Gross margin expanded to 41.7% from 30.5%, driven by operating leverage in lab model.
CEO Jonathan Cohen presented at the Next Generation Dx Summit on MCED and prevention strategies.
Company aims to test over 35,000 firefighters by year-end through state-funded programs.
OneTest platform evolution includes at-home capillary blood collection for quarterly monitoring.

The big picture

20/20 BioLabs is capitalizing on growing demand for early cancer detection, with its OneTest platform at the center of a broader shift toward preventive healthcare. The company's record revenue and expanding gross margins signal operational efficiency, while its strategic focus on firefighter screening programs and regulatory pathways positions it for long-term growth. The evolution of its testing platform could further accelerate adoption as it moves toward at-home monitoring solutions.

What we're watching

Commercial Momentum: Whether 20/20 BioLabs can sustain its 47.1% YoY revenue growth as it expands into new channels.
Regulatory Pathway: The pace at which the company can leverage real-world evidence to support its 2028 Medicare pathway.
Product Evolution: How the shift to at-home capillary blood collection will impact adoption and scalability.